Minerva Neurosciences, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Minerva Neurosciences, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2020 | $41.18M | Mar 1, 2022 |
| FY2017 | Dec 31, 2017 | $0 | Mar 12, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | Feb 25, 2025 |
| FY2023 | Dec 31, 2023 | $0 | Feb 22, 2024 |
| FY2022 | Dec 31, 2022 | $0 | Mar 8, 2023 |
| FY2021 | Dec 31, 2021 | $0 | Mar 1, 2022 |
| FY2020 | Dec 31, 2020 | $0 | Mar 8, 2021 |
| FY2020 | Jun 30, 2020 | $41.18M | Mar 8, 2021 |
| FY2019 | Dec 31, 2019 | $0 | Mar 9, 2020 |
| FY2018 | Dec 31, 2018 | $0 | Mar 12, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($293.42M) | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $1.44M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | ($30.01M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | ($32.11M) | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | ($49.91M) | Mar 8, 2023 |
| FY2020 | Dec 31, 2020 | ($7.32M) | Mar 8, 2021 |
| FY2020 | Sep 30, 2020 | ($8.11M) | Mar 8, 2021 |
| FY2020 | Jun 30, 2020 | $29.53M | Mar 8, 2021 |
| FY2020 | Mar 31, 2020 | ($12.15M) | Mar 8, 2021 |
| FY2020 | Dec 31, 2019 | ($29.92M) | Mar 8, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($15.10M) | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | ($21.85M) | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | ($23.12M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | ($25.23M) | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | ($45.37M) | Mar 8, 2023 |
| FY2020 | Dec 31, 2020 | ($7.30M) | Mar 8, 2021 |
| FY2020 | Sep 30, 2020 | ($8.09M) | Mar 8, 2021 |
| FY2020 | Jun 30, 2020 | $29.51M | Mar 8, 2021 |
| FY2020 | Mar 31, 2020 | ($12.27M) | Mar 8, 2021 |
| FY2020 | Dec 31, 2019 | ($32.37M) | Mar 8, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.76M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $11.90M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $12.71M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $14.65M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $32.04M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $22.04M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $58.12M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $34.89M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $30.26M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $20.44M | Mar 12, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($13.51M) | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | ($19.55M) | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | ($14.78M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | ($24.65M) | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | ($24.60M) | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | ($33.82M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($43.43M) | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | ($41.94M) | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $3.09M | Mar 12, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2022 | $16.3K | Feb 22, 2024 |
| FY2018 | Dec 31, 2017 | $52.4K | Mar 12, 2019 |
| FY2016 | Dec 31, 2014 | $45.6K | Mar 13, 2017 |
| FY2014 | Dec 31, 2013 | $3.2K | Mar 26, 2015 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $97.97M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $37.14M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $56.90M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $55.09M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $77.12M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $57.63M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $77.50M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $139.14M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $183.70M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $132.94M | Mar 12, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $233.76M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $62.84M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $85.36M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $75.11M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $69.15M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $4.96M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $49.72M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $48.87M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $52.10M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $26.96M | Mar 12, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($140.75M) | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | ($25.69M) | Mar 11, 2026 |
| FY2025 | Dec 31, 2023 | ($28.46M) | Mar 11, 2026 |
| FY2024 | Dec 31, 2022 | ($20.02M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $7.98M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $52.66M | Mar 8, 2023 |
| FY2021 | Dec 31, 2019 | $27.78M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $90.26M | Mar 8, 2021 |
| FY2019 | Dec 31, 2017 | $131.60M | Mar 9, 2020 |
| FY2018 | Dec 31, 2016 | $105.98M | Mar 12, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.87M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $14.87M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $14.87M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $14.87M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $14.87M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $14.87M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $14.87M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $14.87M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $14.87M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $14.87M | Mar 12, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($688.80M) | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | ($395.38M) | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | ($396.82M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | ($366.81M) | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | ($334.70M) | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | ($284.80M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($286.74M) | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | ($214.55M) | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | ($164.38M) | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | ($132.86M) | Mar 12, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $82.30M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $21.36M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $40.91M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $36.09M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $60.76M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $25.36M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $21.41M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $50.23M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $26.05M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $82.98M | Mar 12, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (34) | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | (4) | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | (6) | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | (9) | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | (1) | Mar 8, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (34) | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | (4) | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | (6) | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | (9) | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | (1) | Mar 8, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 43.27M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | 6.99M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | 6.99M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | 5.34M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | 5.34M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | 42.72M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 39.08M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | 38.94M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | 38.75M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | 35.02M | Mar 12, 2018 |